StockDriftsStockDriftsCYBIN INC. has 12 SEC filings in the last 90 days, latest: Chief Growth Officer buys $1.25M of common shares (4, September 11, 2026). Each filing below is summarised from the document itself and links straight to the original on SEC EDGAR.
Of the 12 filings tracked here, 7 report insider buys. See only CYBN Form 4 filings.
Paul Glavine, Chief Growth Officer, bought 100,000 common shares for $1,247,190.00 in an open-market transaction.
Paul Glavine, Chief Growth Officer, bought 100,000 shares for $1,247,190 in an open-market transaction.
Executive Chair Eric H. L. So bought 100,000 common shares for $1,238,670.00.
Executive Chair Eric H. L. So bought 100,000 shares for $1,208,900.00 in an open-market transaction.
Paul Glavine, Chief Growth Officer, bought 100,000 shares for $1,178,280.00 in an open-market transaction.
Executive Chair Eric H. L. So bought 95,000 common shares for $1,121,475.00 in an open-market transaction.
Paul Glavine, Chief Growth Officer, bought 90,000 common shares for a total of $1,042,677.00.
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference.
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference.
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Cantor Global Healthcare Conference on September 11, 2026.
Executive Chairman Eric So reported beneficial ownership of 5.8% of outstanding shares and purchased $1,121,475 of common shares.
Paul Glavine, Chief Growth Officer, and the PLG Family Trust, reported a combined beneficial ownership of 5.8% of common shares.